



## Amelia Feulner Baur, PhD

*Founding Partner*

### Personalized representation from a leader in precision medicine and biologics patent law

Amelia Feulner Baur's practice covers a broad spectrum of intellectual property issues, including patent preparation and prosecution, coordination of worldwide patent strategies, appeals to the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office and the Court of Appeals for the Federal Circuit (CAFC). Amelia has been recognized as an IP Star by both Managing Intellectual Property and LMG Life Sciences.

She has extensive experience working with clients to develop effective patent strategies to meet business goals. This includes landscape analyses, due diligence investigations, and providing patentability, freedom-to-operate, infringement, and validity opinions. In addition, Amelia has led clients through inter partes review (IPR), reexaminations, interferences, and the settlement of patent disputes. She has worked with biotech startups, research foundations, and larger, established pharmaceutical companies.

Amelia earned her PhD degree in molecular microbiology, where she gained extensive hands-on experience in the fields of microbiology, immunology, biochemistry, molecular biology, and infectious disease. She has substantial legal experience in many biotechnology and pharmaceutical practice areas including antibodies and antibody variants, diagnostic and detection methods, protein purification, vaccine technology, fusion proteins, gene cloning and expression, and gene and protein mutations.

Prior to founding McNeill Baur PLLC, Amelia spent more than a decade at two large IP firms: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP and Nixon Peabody, LLP.

She is married to Dr. Joseph Baur, Associate Professor in the Department of Physiology and Institute for Diabetes, Obesity and Metabolism, at Perelman School of Medicine at the University of Pennsylvania.

610.667.2014  
amelia.baur@mcneillbaur.com  
McNeill Baur PLLC  
Two Bala Plaza  
Suite 300, #507  
Bala Cynwyd, PA 19004

#### **Admissions**

Pennsylvania  
Massachusetts  
US Patent and Trademark Office  
US Court of Appeals, Federal Circuit (CAFC)  
US Supreme Court  
US Court of Appeals, Veterans Claims (CAVC)

#### **Education**

Suffolk University Law School  
JD, 2008

The University of Texas  
Southwestern Medical Center at Dallas  
PhD, Molecular Microbiology, 2003

Russell Sage College  
BA, Biology, 1998, magna cum laude,  
highest honors

## Recognition

2023 Managing IP Patent Star  
2023 IAM Patent 1000 Recommended Individual  
2023 Top 250 Women in IP, Managing Intellectual Property IP Stars  
2022 LMG Life Sciences Leading Life Science Lawyer, Patent Prosecution, Patent Strategy & Management  
2016-2021 IAM Patent 1000, Leading Patent Professional  
2016-2018 IP Star, Managing Intellectual Property  
2017-2021 IP Star, LMG Life Sciences  
2019 SuperLawyer  
2016 -2018 Rising Star, SuperLawyers



Amelia Feulner Baur, PhD

## Leadership Roles

American Bar Association (ABA), Chair, Section of Intellectual Property Law: Patents in the Chemical and Life Sciences (beginning Sept 2017); Vice-Chair (2015-2017)

## Selected Publications

“Navigating through the Obviousness-Type Double Patenting Minefield,” *Landslide* 10 (3), January/February 2018 (coauthor).

“Navigating the Limitations on Discovery in AIA Post-Grant Proceedings,” *Buffalo Intellectual Property Law Journal*, December 3, 2015 (coauthor).

“US Supreme Court Provides New Hurdles for Personalized Medicine in *Limelight Networks v. Akamai Technologies*,” *Bloomberg BNA, World Intellectual Property Report*, September 2014.

“Comments of the American Bar Association Section of Intellectual Property in Response to the USPTO’s Guidance for Determining Subject Matter Eligibility of Claims Reciting or Involving Laws of Nature, Natural Phenomena & Natural Products,” July 30, 2014 (coauthor).

“Ask The Expert: Are Diagnostic Patents Dead?,” *Clinical Laboratory News* 40(7):44 (2014).

“Personalized Medicine Patents at Risk: Tips for Battling Prometheus and Myriad to Obtain Claims to Diagnostics,” *CIPA Journal*, March 2013 (coauthor).

“Patenting Personalized Medicine,” *The Journal of Biolaw and Business*, 2006 (coauthor).

“Creating and Enforcing Patent Rights in the Fast Moving Field of Personalized Medicine,” *The Journal of Biolaw and Business*, 2006 (coauthor).

“Identification of Acyloxyacyl Hydrolase, a LipopolySaccharide-Detoxifying Enzyme, in the Murine Urinary Tract,” *Infection and Immunity*, June 2004 (coauthor).

## Selected Speaking Engagements

BIO Intellectual Property Counsels Committee Conference, “When On Time is Late: Expediting US and Foreign Issuance,” Boston, MA, November 16, 2023.

Amelia Feulner Baur, PhD

Strafford Publications Webinar, "Application of Section 101 in Life Sciences Patents: Leveraging Revised USPTO Guidelines," August 15, 2019.

Strafford Publications Webinar, "Double Patenting: Defeating Double Patenting Rejections And Avoiding Terminal Disclaimers," June 21, 2018.

ABA Annual Intellectual Property Law Conference, "Growing Your Start-UP IP Practice," Arlington, VA, April 19, 2018.

Strafford Publications Webinar, "Sect. 112 Indefiniteness in Chemical and Biotech Patent Claims," February 14, 2018.

Strafford Publications Webinar, "Strategic Use of Patent Reissue: Whether and When to Pursue a Reissue Application," January 18, 2018.

Strafford Publications Webinar, "Overcoming §103 Rejections for Biotech and Chemical Patents: Recent Decisions and USPTO Guidance," November 16, 2017.

Managing Intellectual Property (MIP) International Women's Leadership Forum, "Licensing Agreements and Royalties," New York City, June 8, 2017.

The Knowledge Group Webinar, "USPTO's Subject Matter Eligibility: The Dos and Don'ts in 2016 and Beyond," November 15, 2016."

The Institute of Professional Representatives before the European Patent Office (epi), "Recent Developments, Key Case Law and Current Landscape of Patent Eligibility," Eindhoven, The Netherlands, November 20, 2015.

AIPLA Biotech Patent Law Road Show, "Divided Infringement and Claim Drafting in a Post-Myriad, Mayo, Akamai, Ariosa World," Boston, MA, September 10, 2015.

Strafford Publications Webinar, "Patent Subject Matter Eligibility: Navigating the New 'Myriad' Guidelines," April 16, 2014, and May 15, 2014.

BPLA, Moderator, "Hot Topics in European and US Patent Law: Comparing, Contrasting, and Harmonizing Strategies with Focus on Post-Grant Proceedings, Unitary Patent System, Biosimilars, and Patent Misuse," April 1, 2014.